{"id":"https://openalex.org/W2149166282","doi":"https://doi.org/10.2217/cpr.13.24","title":"Nilotinib for treatment of chronic myeloid leukemia in light of the current evidence and guidelines","display_name":"Nilotinib for treatment of chronic myeloid leukemia in light of the current evidence and guidelines","publication_year":2013,"publication_date":"2013-05-01","ids":{"openalex":"https://openalex.org/W2149166282","doi":"https://doi.org/10.2217/cpr.13.24","mag":"2149166282"},"language":"en","primary_location":{"id":"doi:10.2217/cpr.13.24","doi":"https://doi.org/10.2217/cpr.13.24","is_oa":false,"landing_page_url":"https://doi.org/10.2217/cpr.13.24","pdf_url":null,"source":{"id":"https://openalex.org/S4210240611","display_name":"Clinical Practice","issn_l":"2044-9038","issn":["2044-9038","2044-9046"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","poland-20"],"host_organization":"https://openalex.org/P4310320466","host_organization_name":"OMICS Publishing Group","host_organization_lineage":["https://openalex.org/P4310320466"],"host_organization_lineage_names":["OMICS Publishing Group"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Practice","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2149166282"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5020109084","display_name":"Pratap Neelakantan","orcid":"https://orcid.org/0000-0002-8693-6605","observed_orcids":["https://orcid.org/0000-0002-8693-6605"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pratap Neelakantan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5074115908","display_name":"Jane F. Apperley","orcid":"https://orcid.org/0000-0002-1710-1794","observed_orcids":["https://orcid.org/0000-0002-1710-1794"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jane F Apperley","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"10","issue":"3","first_page":"283","last_page":"291"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nilotinib","display_name":"nilotinib","score":1.0},{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":1.0},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9850000143051147},{"id":"https://openalex.org/keywords/imatinib-resistance","display_name":"imatinib resistance","score":0.8709999918937683},{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":0.8240000009536743},{"id":"https://openalex.org/keywords/bosutinib","display_name":"bosutinib","score":1.0},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.6320000290870667},{"id":"https://openalex.org/keywords/upfront-therapy","display_name":"upfront therapy","score":0.7739999890327454},{"id":"https://openalex.org/keywords/adverse-effects","display_name":"adverse effects","score":0.875},{"id":"https://openalex.org/keywords/treatment-guidelines","display_name":"treatment guidelines","score":0.7139999866485596}],"concepts":[{"id":"https://openalex.org/C2777413986","wikidata":"https://www.wikidata.org/wiki/Q412327","display_name":"Nilotinib","level":4,"score":0.9009631872177124},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.7940423488616943},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5837651491165161},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.47087347507476807},{"id":"https://openalex.org/C148043351","wikidata":"https://www.wikidata.org/wiki/Q4456944","display_name":"Current (fluid)","level":2,"score":0.4194667935371399},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4071665108203888},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.37077009677886963},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.12583670020103455},{"id":"https://openalex.org/C127313418","wikidata":"https://www.wikidata.org/wiki/Q1069","display_name":"Geology","level":0,"score":0.07571515440940857},{"id":"https://openalex.org/C111368507","wikidata":"https://www.wikidata.org/wiki/Q43518","display_name":"Oceanography","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2217/cpr.13.24","doi":"https://doi.org/10.2217/cpr.13.24","is_oa":false,"landing_page_url":"https://doi.org/10.2217/cpr.13.24","pdf_url":null,"source":{"id":"https://openalex.org/S4210240611","display_name":"Clinical Practice","issn_l":"2044-9038","issn":["2044-9038","2044-9046"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","poland-20"],"host_organization":"https://openalex.org/P4310320466","host_organization_name":"OMICS Publishing Group","host_organization_lineage":["https://openalex.org/P4310320466"],"host_organization_lineage_names":["OMICS Publishing Group"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Practice","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":46,"referenced_works":["https://openalex.org/W1509074151","https://openalex.org/W1799579309","https://openalex.org/W1826395562","https://openalex.org/W1977177366","https://openalex.org/W1987316203","https://openalex.org/W1997026783","https://openalex.org/W1998936478","https://openalex.org/W2005515343","https://openalex.org/W2008933596","https://openalex.org/W2009746825","https://openalex.org/W2012455926","https://openalex.org/W2016809033","https://openalex.org/W2041004587","https://openalex.org/W2051566553","https://openalex.org/W2054251966","https://openalex.org/W2057718276","https://openalex.org/W2058677025","https://openalex.org/W2066099870","https://openalex.org/W2068248632","https://openalex.org/W2072834954","https://openalex.org/W2076720738","https://openalex.org/W2076877348","https://openalex.org/W2105747906","https://openalex.org/W2106555552","https://openalex.org/W2107268345","https://openalex.org/W2115732289","https://openalex.org/W2124196948","https://openalex.org/W2134566943","https://openalex.org/W2143939343","https://openalex.org/W2146658081","https://openalex.org/W2155615242","https://openalex.org/W2158884958","https://openalex.org/W2166270808","https://openalex.org/W2171188310","https://openalex.org/W2172189430","https://openalex.org/W2172242821","https://openalex.org/W2261840157","https://openalex.org/W2304674089","https://openalex.org/W2314938037","https://openalex.org/W2344087471","https://openalex.org/W2522083081","https://openalex.org/W2552922406","https://openalex.org/W2575129937","https://openalex.org/W2584586486","https://openalex.org/W2596224382","https://openalex.org/W2979821888"],"related_works":["https://openalex.org/W1974135663","https://openalex.org/W2072665415","https://openalex.org/W2005106433","https://openalex.org/W4254461073","https://openalex.org/W2556260578","https://openalex.org/W2120868842","https://openalex.org/W1985481617","https://openalex.org/W1975684789","https://openalex.org/W2031077231","https://openalex.org/W2001289393"],"abstract_inverted_index":{"SUMMARY\u00a0The":[0],"introduction":[1],"of":[2,29,41,58],"the":[3,17,27,39],"tyrosine":[4,31],"kinase":[5,32],"inhibitor":[6],"imatinib,":[7],"a":[8,11],"little":[9],"over":[10],"decade":[12],"ago,":[13],"has":[14],"greatly":[15],"improved":[16],"prognosis":[18],"for":[19,68,88],"patients":[20],"with":[21,26],"chronic":[22],"myeloid":[23],"leukemia.":[24],"Now":[25],"availability":[28],"second-generation":[30],"inhibitors":[33],"we":[34,74],"anticipate":[35],"further":[36],"improvements":[37],"in":[38],"outcome":[40],"this":[42,72],"disease.":[43],"These":[44],"agents,":[45],"namely":[46],"nilotinib,":[47,77],"dasatinib":[48],"and":[49,82,85],"bosutinib,":[50],"have":[51],"not":[52],"only":[53],"been":[54],"effective":[55],"at":[56],"treatment":[57],"imatinib-resistant":[59],"and/or":[60],"-intolerant":[61],"patients,":[62],"but":[63],"are":[64],"increasingly":[65],"being":[66],"advocated":[67],"upfront":[69],"usage.":[70,90],"In":[71],"review,":[73],"focus":[75],"on":[76],"its":[78,89],"pharmacology,":[79],"clinical":[80],"indications":[81],"side":[83],"effects,":[84],"suggest":[86],"guidelines":[87]},"counts_by_year":[{"year":2020,"cited_by_count":1}],"updated_date":"2026-11-14T11:04:58.165337","created_date":"2016-06-24T00:00:00"}